论文部分内容阅读
目的:研究IL-4,IL-12在宫颈癌组织中的表达,探讨其对宫颈癌发生及术后对紫杉醇过敏的影响。方法:应用半定量逆反应-聚合酶链反应(RT-PCR)技术检测IL-4mRNA,IL-12p35以及IL-12p40 mRNA在正常宫颈组和宫颈癌组中的表达,并分析两者之间的相关性以对紫杉醇过敏的影响。结果:1.宫颈癌组中IL-4mRNA表达水平高于正常宫颈组,而IL-12p35和IL-12p40mRNA表达低于正常宫颈组,差异有统计学意义(P<0.05);2.在术后给予紫杉醇治疗的宫颈癌患者中,过敏组中IL-4mRNA的表达高于不过敏组;IL-12p35和IL-12p40mRNA则低于后者,差异有统计学意义(P<0.05)。结论:体内IL-12降低和(或)IL-4升高可促进宫颈癌的发生发展增加紫杉醇过敏的发生率。
Objective: To study the expression of IL-4 and IL-12 in cervical cancer and to investigate the effect of IL-4 and paclitaxel on the occurrence of cervical cancer and postoperative allergy to paclitaxel. Methods: The expressions of IL-4 mRNA, IL-12p35 and IL-12p40 mRNA in normal cervix and cervical cancer were detected by semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) Sex with the impact of paclitaxel allergy. The expression of IL-4 mRNA in cervical cancer group was higher than that in normal cervix group, while the expression of IL-12p35 and IL-12p40 mRNA in cervical cancer group was lower than that in normal cervix group (P <0.05) .2. In patients with cervical cancer treated with paclitaxel, the expression of IL-4mRNA in allergic group was higher than that in non-allergic group, while the levels of IL-12p35 and IL-12p40mRNA were lower than the latter (P <0.05). Conclusion: The decrease of IL-12 and / or IL-4 in vivo may promote the occurrence and development of cervical cancer and increase the incidence of paclitaxel allergy.